Swedish Orphan Biovitrum AB (DE:B6E)
FRANKFURT:B6E
Want to see DE:B6E full AI Analyst Report?
B6E Stock Chart & Stats
€36.06
-€0.20(-0.72%)
At close: 4:00 PM EST
€36.06
-€0.20(-0.72%)
Day’s Range― - ―
52-Week Range€23.62 - €40.94
Previous CloseN/A
Volume0.00
Average Volume (3M)45.00
Market Cap
€13.80B
Enterprise Value€168.63B
Total Cash (Recent Filing)€940.00M
Total Debt (Recent Filing)€19.06B
Price to Earnings (P/E)25.7
Beta1.05
Next Earnings
Jul 21, 2026EPS Estimate
0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.65
Shares Outstanding357,412,840
10 Day Avg. Volume55
30 Day Avg. Volume45
Financial Highlights & Ratios
PEG Ratio-2.73
Price to Book (P/B)3.04
Price to Sales (P/S)4.06
P/FCF Ratio13.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€43.27Price Target Upside20.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.64
Revenue Forecast (FY)€2.93B
Bulls Say, Bears Say
Bulls Say
Specialty Rare-disease FocusSobi’s focus on high‑unmet‑need rare diseases creates durable demand, pricing power and sticky customer relationships. A specialty portfolio plus lifecycle management and in‑/out‑licensing supports steady product revenue and long product lifecycles versus acute therapies.
Strong Revenue Momentum And Cash GenerationConsistent TTM revenue growth and positive operating and free cash flow indicate core business generates cash to fund R&D, commercialization and partnerships. Cash‑backed earnings reduce reliance on external financing over the medium term.
Manageable Leverage / Balance Sheet FlexibilityLow debt-to-equity and a sizable equity base provide financial flexibility to support continued clinical development, geographic rollouts or opportunistic licensing/M&A without immediate balance sheet strain under normal operating conditions.
Bears Say
Deteriorated Net Profitability And ReturnsA marked fall in net profit margin and TTM ROE signals weakening earnings quality and reduced capital returns. If sustained, this lowers internal funding for growth initiatives, increases dependence on partners or external financing, and compresses long‑term investor returns.
Free Cash Flow Decline And Historical VolatilityAlthough FCF is currently positive, recent decline and past negative periods highlight inconsistency in cash conversion. Volatile FCF complicates planning for R&D, launches and milestone payments, and raises execution risk for sustaining growth investments.
Recent Increase In Total DebtAn uptick in absolute debt amid weaker earnings reduces cushion from a previously conservative leverage profile. Higher indebtedness coupled with lower profitability can constrain strategic optionality and increase refinancing or covenant risk in stressed scenarios.
Swedish Orphan Biovitrum AB News
B6E FAQ
What was Swedish Orphan Biovitrum AB’s price range in the past 12 months?
Swedish Orphan Biovitrum AB lowest stock price was €23.62 and its highest was €40.94 in the past 12 months.
What is Swedish Orphan Biovitrum AB’s market cap?
Swedish Orphan Biovitrum AB’s market cap is €13.80B.
When is Swedish Orphan Biovitrum AB’s upcoming earnings report date?
Swedish Orphan Biovitrum AB’s upcoming earnings report date is Jul 21, 2026 which is in 70 days.
How were Swedish Orphan Biovitrum AB’s earnings last quarter?
Swedish Orphan Biovitrum AB released its earnings results on Apr 28, 2026. The company reported €0.35 earnings per share for the quarter, beating the consensus estimate of €0.334 by €0.016.
Is Swedish Orphan Biovitrum AB overvalued?
According to Wall Street analysts Swedish Orphan Biovitrum AB’s price is currently Undervalued.
Does Swedish Orphan Biovitrum AB pay dividends?
Swedish Orphan Biovitrum AB does not currently pay dividends.
What is Swedish Orphan Biovitrum AB’s EPS estimate?
Swedish Orphan Biovitrum AB’s EPS estimate is 0.3.
How many shares outstanding does Swedish Orphan Biovitrum AB have?
Swedish Orphan Biovitrum AB has 357,412,840 shares outstanding.
What happened to Swedish Orphan Biovitrum AB’s price movement after its last earnings report?
Swedish Orphan Biovitrum AB reported an EPS of €0.35 in its last earnings report, beating expectations of €0.334. Following the earnings report the stock price went up 0.163%.
Which hedge fund is a major shareholder of Swedish Orphan Biovitrum AB?
Currently, no hedge funds are holding shares in DE:B6E
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
B6E Stock 12 Month Forecast
Average Price Target
€43.27
▲(20.01% Upside)
Technical Analysis
Orexo AB
―
AlzeCure Pharma AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enorama Pharma AB
―
Options Prices
Currently, No data available
---